Kodiak Sciences reported that its Phase 3 DAYBREAK trial in wet age-related macular degeneration met primary endpoints for both Zenkuda and tabirafusp-ted, with non-inferior vision gains to ...
Source LinkKodiak Sciences reported that its Phase 3 DAYBREAK trial in wet age-related macular degeneration met primary endpoints for both Zenkuda and tabirafusp-ted, with non-inferior vision gains to ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.